Introduction & Filtering Questions

The purpose of the survey is to provide the  Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing prostate cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for non-metastatic castration-resistant prostate cancer called darolutamide.

The survey will remain open until August 30, 2019. 

The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.
 
At this time we are looking primarily for patients with non-metastatic castration-resistant prostate cancer and their caregivers who would be also interested in participating in this survey. If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.

Thank you for your participation.  

Question Title

* 1. Are you a resident of Canada?

Question Title

* 2. If you are a resident of Canada, what province or territory do you reside in?

Question Title

* 3. If you are not a resident of Canada, what country are you from?

Question Title

* 4. What gender do you identify as?

Question Title

* 5. What methods were used to diagnose the cancer in you or your loved one? Please choose all that apply, and use the comment box for additional information if applicable.

Question Title

* 6. Are you a prostate cancer patient or a caregiver?

0 of 40 answered
 

T